Devyser Diagnostics (DVYSR) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue reached SEK 54.8 million, up 7.9% year-over-year, with gross margin improving to 83.4% from 82.7%.

• EBIT was SEK -20.5 million, impacted by SEK 8 million in restructuring costs and SEK 6 million in FX headwinds, widening from SEK -12.2 million year-over-year.

• Cash position at quarter-end was SEK 114 million, with no debt, supporting ongoing investments.

• Strategic focus sharpened on clinical genetics and transplantation labs, with new product launches, regulatory milestones, and major tenders in Italy.

• Organizational restructuring and cost-saving initiatives executed to drive efficiency and support profitability targets.

Financial highlights

• Revenue grew 7.9% year-over-year to SEK 54.8 million, but declined sequentially from SEK 64.2 million in Q4 2024.

• Gross margin rebounded to 83.4% after a soft 2024, reflecting operational improvements.

• EBIT was SEK -20.5 million, including SEK 8 million in one-off restructuring costs and SEK 6 million in negative FX impact.

• Cash and cash equivalents at quarter-end were SEK 114 million.

• EPS was SEK -1.24, down from SEK -0.75 year-over-year.

Outlook and guidance

• Confident in achieving 30% organic growth target for 2025 and 20% EBIT margin by 2026.

• Growth expected to be weighted toward the second half of 2025, with new product launches and reimbursement milestones anticipated.

• No change to full-year guidance despite quarterly fluctuations.

• Focus remains on cost structure improvements and cash flow strengthening throughout 2025.

• New CEO Jan Wahlström to start in August 2025, with a transition period planned.